Metagenomi Therapeutics To Present Presentation On Preclinical Data Of MGX-001 At 68th American Society Of Hematology Annual Meeting
Benzinga Newsdesk 2 weeks ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Dr. Alan Brooks, Senior Vice President of Research at the Company, will deliver an oral presentation on preclinical data supporting MGX-001 at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana.
